BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Taha MK, Gaudelus J, Deghmane AE, Caron F. Recent changes of invasive meningococcal disease in France: arguments to revise the vaccination strategy in view of those of other countries. Hum Vaccin Immunother 2020;16:2518-23. [PMID: 32209010 DOI: 10.1080/21645515.2020.1729030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Hong E, Terrade A, Muzzi A, De Paola R, Boccadifuoco G, La Gaetana R, Deghmane AE, Pizza M, Serino L, Taha MK. Evolution of strain coverage by the multicomponent meningococcal serogroup B vaccine (4CMenB) in France. Hum Vaccin Immunother 2021;:1-9. [PMID: 34856875 DOI: 10.1080/21645515.2021.2004055] [Reference Citation Analysis]
2 Taha MK, Weil-Olivier C, Bouée S, Emery C, Nachbaur G, Pribil C, Loncle-Provot V. Risk factors for invasive meningococcal disease: a retrospective analysis of the French national public health insurance database. Hum Vaccin Immunother 2021;17:1858-66. [PMID: 33449835 DOI: 10.1080/21645515.2020.1849518] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Cohen R, Ashman M, Taha MK, Varon E, Angoulvant F, Levy C, Rybak A, Ouldali N, Guiso N, Grimprel E. Pediatric Infectious Disease Group (GPIP) position paper on the immune debt of the COVID-19 pandemic in childhood, how can we fill the immunity gap? Infect Dis Now 2021;51:418-23. [PMID: 33991720 DOI: 10.1016/j.idnow.2021.05.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
4 Walter S, Gil-Prieto R, Gil-Conesa M, Rodriguez-Caravaca G, San Román J, Gil de Miguel A. Hospitalizations related to meningococcal infection in Spain from 1997 to 2018. BMC Infect Dis 2021;21:1215. [PMID: 34872512 DOI: 10.1186/s12879-021-06916-9] [Reference Citation Analysis]
5 Nuttens C, Findlow J, Balmer P, Swerdlow DL, Tin Tin Htar M. Evolution of invasive meningococcal disease epidemiology in Europe, 2008 to 2017. Eurosurveillance 2022;27. [DOI: 10.2807/1560-7917.es.2022.27.3.2002075] [Reference Citation Analysis]
6 Shen J, Bouée S, Aris E, Emery C, Beck EC. Long-Term Mortality and State Financial Support in Invasive Meningococcal Disease-Real-World Data Analysis Using the French National Claims Database (SNIIRAM). Infect Dis Ther 2021. [PMID: 34791633 DOI: 10.1007/s40121-021-00546-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Martinón-Torres F, Bertrand-Gerentes I, Oster P. A novel vaccine to prevent meningococcal disease beyond the first year of life: an early review of MenACYW-TT. Expert Rev Vaccines 2021;:1-24. [PMID: 34365870 DOI: 10.1080/14760584.2021.1964962] [Reference Citation Analysis]